Boston Scientific (BSX) Tops Q2 EPS by 4c; offers guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to Boston Scientific (BSX) Tops Q2 EPS by 4c; offers guidance
July 25, 2024 5:07 AM EDT
Deutsche Bank analyst Pito Chickering raised the price target on Boston Scientific (NYSE: BSX) to $78.00 (from $73.00) while maintaining a Hold rating.
The analyst comments "All told, Boston continues to execute at a high level, with continued portfolio shift to higher-growth segments (WAMGR has increased to HSD from LSD historically), leaving the... More
July 24, 2024 1:39 PM EDT
Jefferies analyst Matthew Taylor raised the price target on Boston Scientific (NYSE: BSX) to $90.00 (from $82.00) while maintaining a Buy rating.
The analyst comments "BSX reported 2Q24 sales of $4.12B, +14.7% organic, vs cons $4.02B and EPS of $0.62 +17%. vs cons $0.58. BSX increased '24 guidance to... More
July 24, 2024 12:30 PM EDT
BTIG analyst Marie Thibault reiterated a Buy rating and $84.00 price target on Boston Scientific (NYSE: BSX).
The analyst comments "This was another impressive quarter from Boston Scientific. Yet with the stock seemingly priced for perfection, shares traded off on Wednesday morning as a beat was widely anticipated and investors focused on whether the strong growth can be sustained beyond the Farapulse launch. BSX reported Q2 revenue of $4.120B (+14.5% y/y rep., +14.7% y/y org.) and adj. EPS of $0.62 (consensus $4.021B and $0.58), besting its guidance of +10.5-12.5% y/y reported sales growth,... More
July 24, 2024 12:04 PM EDT
Evercore ISI analyst Vijay Kumar raised the price target on Boston Scientific (NYSE: BSX) to $82.00 (from $81.00) while maintaining a Outperform rating.
The analyst comments "Thesis Update: BSX reported an overall organic growth of ~14.7% and EPS growth of ~16%...while these are numbers that any company can be proud of, BSX shares are down -3% as we write this. We would notch the share reaction to the expectations game, which seems a little odd to us given that consensus trades have worked so far (ISRG up DD on hitting buyside expecs for systems).... More
July 24, 2024 7:37 AM EDT
Citi analyst Joanna Wuensch reiterated a Buy rating and $90.00 price target on Boston Scientific (NYSE: BSX).
The analyst comments "BSX delivered a strong 2Q24 results ahead of expectations with revenue of $4.12B (up 14.7% organic, ahead of consensuss $4.02B). The beat was broad based,... More
